EyePoint Pharmaceuticals, Inc. has released its latest data and updates at the TD Cowen Healthcare Conference. The company boasts a robust safety profile for its Durasert® drug delivery system and reports having approximately $370 million in cash and equivalents as of December 31, 2024, providing a cash runway into 2027 post Phase 3 readouts in 2026.
The company's DURAVYU™, a vorolanib in Durasert E™ sustained delivery technology, has shown highly positive Phase 2 data in the treatment of Diabetic Macular Edema (DME). In the DAVIO 2 clinical trial for wet Age-Related Macular Degeneration (AMD), DURAVYU demonstrated statistically non-inferior best-corrected visual acuity (BCVA) compared to aflibercept, with over 80% reduction in treatment burden.
EyePoint Pharmaceuticals also highlights its state-of-the-art cGMP manufacturing facility in Northbridge, MA, which is ready to support DURAVYU through Phase 3 and global commercial production.
The Phase 2 VERONA Clinical Trial for DME showed that a single DURAVYU 2.7mg treatment led to a greater proportion of supplement-free eyes compared to the aflibercept control at 24 weeks. The trial also revealed that DURAVYU demonstrated clinically meaningful improvement in BCVA and controlled anatomy, with 74% more drying than the aflibercept control.
The company's Phase 3 pivotal trials for DURAVYU in wet AMD are seeing exceptional enrollment rates, with the LUGANO trial having over 50% enrolled and the LUCIA trial exceeding expectations.
EyePoint Pharmaceuticals' press release outlines a promising outlook for DURAVYU in the treatment of retinal diseases, with positive data across multiple indications and significant progress in its clinical development. The market has reacted to these announcements by moving the company's shares 7.5% to a price of $6.15. If you want to know more, read the company's complete 8-K report here.
